$NEPH
NEPHROS INC Stock $neph

$neph Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000114420415047743 Filed on August 10, 2015

Income Statement

Concept	2015 Q2	2014 Q4	2014 Q2
Revenue	$521.0K	$340.0K	$441.0K
YoY Change	18.14%	47.83%	-23.3%
Cost Of Revenue	$209.0K	$130.0K	$142.0K
YoY Change	47.18%	-55.17%	-37.17%
Gross Profit	$312.0K	$220.0K	$299.0K
YoY Change	4.35%	-466.67%	-14.33%
Gross Profit Margin	59.88%	64.71%	67.8%
Selling, General & Admin	$740.0K	$690.0K	$700.0K
YoY Change	5.71%	-11.54%	6.06%
% of Gross Profit	237.18%	313.64%	234.11%
Research & Development	$160.0K	$260.0K	$180.0K
YoY Change	-11.11%	44.44%	-30.5%
% of Gross Profit	51.28%	118.18%	60.2%
Depreciation & Amortization	$60.00K	$0.00	$120.0K
YoY Change	-50.0%		1100.0%
% of Gross Profit	19.23%	0.0%	40.13%
Operating Expenses	$952.0K	$1.000M	$935.0K
YoY Change	1.82%	-0.99%	-4.3%
Operating Profit	-$594.0K	-$780.0K	-$636.0K
YoY Change	-6.6%	-27.1%	1.27%
Interest Expense	$9.000K	-$4.480M	$17.00K
YoY Change	-47.06%	-190.87%	-29.17%
% of Operating Profit
Other Income/Expense, Net	-$16.00K	$20.00K	-$1.000K
YoY Change	1500.0%	-300.0%	-94.74%
Pretax Income	-$1.820M	-$5.250M	-$5.340M
YoY Change	-65.92%	-236.36%	697.01%
Income Tax
% Of Pretax Income
Net Earnings	-$1.815M	-$5.250M	-$5.339M
YoY Change	-66.0%	-236.36%	317.44%
Net Earnings / Revenue	-348.37%	-1544.12%	-1210.66%
Basic Earnings Per Share	-$0.06		-$0.21
Diluted Earnings Per Share	-$524.5K	-$1.817M	-$1.907M
COMMON SHARES
Basic Shares Outstanding	31.19M shares	25.26M shares	25.17M shares
Diluted Shares Outstanding	31.19M shares		25.17M shares

Balance Sheet

Concept	2015 Q2	2014 Q4	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.040M	$1.280M	$230.0K
YoY Change	352.17%	120.69%	-23.33%
Cash & Equivalents		$1.280M	$230.0K
Short-Term Investments
Other Short-Term Assets	$60.00K	$104.0K	$59.00K
YoY Change	1.69%	-16.8%	-15.71%
Inventory	$419.0K	$186.0K	$163.0K
Prepaid Expenses
Receivables	$295.0K	$110.0K	$110.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.812M	$1.684M	$560.0K
YoY Change	223.57%	70.45%	-35.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$1.000K	$3.000K
YoY Change	-100.0%	-85.71%	-75.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.579M	$1.684M	$1.789M
YoY Change	-11.74%	-11.09%	-10.55%
Total Long-Term Assets	$1.579M	$1.685M	$1.792M
YoY Change	-11.89%	-11.36%	-10.93%
TOTAL ASSETS
Total Short-Term Assets	$1.812M	$1.684M	$560.0K
Total Long-Term Assets	$1.579M	$1.685M	$1.792M
Total Assets	$3.391M	$3.369M	$2.352M
YoY Change	44.18%	16.61%	-18.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$990.0K	$835.0K	$1.030M
YoY Change	-3.88%	-22.18%	31.04%
Accrued Expenses	$306.0K	$342.0K	$233.0K
YoY Change	31.33%	-6.3%	16.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.364M	$1.247M	$1.684M
YoY Change	-19.0%	-64.36%	-0.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.960M	$7.800M	$450.0K
YoY Change	1668.89%	150.8%	28.57%
Total Long-Term Liabilities	$7.960M	$7.800M	$450.0K
YoY Change	1668.89%	150.8%	28.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.364M	$1.247M	$1.684M
Total Long-Term Liabilities	$7.960M	$7.800M	$450.0K
Total Liabilities	$9.320M	$9.050M	$2.136M
YoY Change	336.33%	36.96%	4.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$115.7M	-$114.2M	-$115.6M
YoY Change	0.08%	6.9%	7.2%
Common Stock	$32.00K	$30.00K	$25.00K
YoY Change	28.0%	66.67%	38.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.929M	-$5.681M	$216.0K
YoY Change
Total Liabilities & Shareholders Equity	$3.391M	$3.369M	$2.352M
YoY Change	44.18%	16.61%	-18.39%

Cashflow Statement

Concept	2015 Q2	2014 Q4	2014 Q2
OPERATING ACTIVITIES
Net Income	-$1.815M	-$5.250M	-$5.339M
YoY Change	-66.0%	-236.36%	317.44%
Depreciation, Depletion And Amortization	$60.00K	$0.00	$120.0K
YoY Change	-50.0%		1100.0%
Cash From Operating Activities	-$530.0K	-$840.0K	-$250.0K
YoY Change	112.0%	-4.55%	-84.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities		$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.230M	$3.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.210M	1.070M	0.000
YoY Change		-17.69%	-100.0%
NET CHANGE
Cash From Operating Activities	-530.0K	-840.0K	-250.0K
Cash From Investing Activities		0.000
Cash From Financing Activities	1.210M	1.070M	0.000
Net Change In Cash	680.0K	230.0K	-250.0K
YoY Change	-372.0%	-45.24%	-600.0%
FREE CASH FLOW
Cash From Operating Activities	-$530.0K	-$840.0K	-$250.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3369000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3391000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-5681000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	-5929000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114165000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115737000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	72000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	71000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	108382000	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	109705000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	30000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	32000	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Liabilities Liabilities	9050000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	9320000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	417000	USD
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	382000	USD
CY2014Q4	neph	Warrant Liability WarrantLiability	7386000	USD
CY2015Q2	neph	Warrant Liability WarrantLiability	7574000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1364000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	342000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	306000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	835000	USD
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32227939	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30391513	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32227939	shares
CY2014Q2	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	7386000	USD
CY2014	neph	Closing Price Per Share Of Common Stock Fair Value ClosingPricePerShareOfCommonStockFairValue	0.79
	neph	Closing Price Per Share Of Common Stock Fair Value ClosingPricePerShareOfCommonStockFairValue	0.71
CY2014	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	1.369	pure
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	1.350	pure
CY2014	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y
CY2015Q2	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	7574000	USD
CY2014	neph	Fair Value Of Calculated Aggregate Value FairValueOfCalculatedAggregateValue	7386	USD
	neph	Fair Value Of Calculated Aggregate Value FairValueOfCalculatedAggregateValue	7574	USD
CY2014	neph	Weighted Average Exercise Price Fair Value WeightedAverageExercisePriceFairValue	0.30
	neph	Weighted Average Exercise Price Fair Value WeightedAverageExercisePriceFairValue	0.30
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P4Y6M
CY2014	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.016	pure
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.016	pure
CY2014	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. Included in these estimates are assumptions about the valuation of the warrant liability, the collection of accounts receivable, value of inventories, useful lives of fixed assets and intangible assets, and assumptions used in determining stock compensation such as expected volatility and risk-free interest rate.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	neph	Warrants Exercised WarrantsExercised	2127	shares
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30391513	shares
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	355000	USD
CY2014Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	55000	USD
CY2015Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	53000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1412000	USD
	us-gaap	Licenses Revenue LicensesRevenue	63000	USD
CY2014Q2	us-gaap	Licenses Revenue LicensesRevenue	193000	USD
CY2015Q2	us-gaap	Licenses Revenue LicensesRevenue	46000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	915000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1112000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	441000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-5339000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-1815000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1573000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1578000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	700000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	521000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	935000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	952000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	467000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1049000	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	248000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-594000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	248000	USD
	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	188000	USD
	us-gaap	Licenses Revenue LicensesRevenue	448000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5340000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1816000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22004712	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30727840	shares
	us-gaap	Gross Profit GrossProfit	667000	USD
	us-gaap	Gross Profit GrossProfit	641000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	299000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25166752	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31190714	shares
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	209000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9000	USD
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In Current Year ExpectedRecognitionOfUnrecognizedCompensationCostsDueInCurrentYear	0.17	pure
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In One Year ExpectedRecognitionOfUnrecognizedCompensationCostsDueInOneYear	0.3	pure
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In Three Years ExpectedRecognitionOfUnrecognizedCompensationCostsDueInThreeYears	0.21	pure
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1398000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5339000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1815000	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22004712	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30727840	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25166752	shares
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	224000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	110000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-636000	USD
	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	7436000	USD
CY2014Q2	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	4685000	USD
CY2015Q2	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	1196000	USD
	us-gaap	Interest Expense InterestExpense	212000	USD
	us-gaap	Interest Expense InterestExpense	21000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	17000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	9000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y9M18D
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1157000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2015Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	59000	USD
CY2014Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	111000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1414000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1198000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8850000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1572000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1384000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-654000	USD
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31190714	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q2	neph	Annual Minimum Amount AnnualMinimumAmount	1000000	EUR
CY2015Q2	neph	Annual Minimum Amount AnnualMinimumAmount	1110000	USD
CY2015Q2	us-gaap	Inventory Gross InventoryGross	478000	USD
CY2014Q4	us-gaap	Inventory Gross InventoryGross	297000	USD
	neph	Amount Of Dilutive Securities Effect On Earnings Per Share Warrants AmountOfDilutiveSecuritiesEffectOnEarningsPerShareWarrants	7436000	USD
	neph	Amount Of Dilutive Securities Effect On Earnings Per Share Warrants AmountOfDilutiveSecuritiesEffectOnEarningsPerShareWarrants	188000	USD
CY2014Q2	neph	Amount Of Dilutive Securities Effect On Earnings Per Share Warrants AmountOfDilutiveSecuritiesEffectOnEarningsPerShareWarrants	4685000	USD
CY2015Q2	neph	Amount Of Dilutive Securities Effect On Earnings Per Share Warrants AmountOfDilutiveSecuritiesEffectOnEarningsPerShareWarrants	1196000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-619000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	1000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	119000	USD
CY2015Q2	neph	Finite Lived Intangible Assets Amortization Expense Years Two And Three FiniteLivedIntangibleAssetsAmortizationExpenseYearsTwoAndThree	210000	USD
CY2015Q2	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	672000	USD
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	105000	USD
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	105000	USD
	neph	Royalty Rate RoyaltyRate	0.03	pure
CY2015Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.12	pure
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	105000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	227000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	119000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	142000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	neph	Inventory Fifo Reserve Period Charge InventoryFifoReservePeriodCharge	31000	USD
	neph	Inventory Fifo Reserve Period Charge InventoryFifoReservePeriodCharge	0	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	NEPHROS INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001196298
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	NEPH
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32227939	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1205000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Note 1 - Organization and Nature of Operations</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. Nephros was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced End Stage Renal Disease (“ESRD”) therapy technology and products. The Company has two products in the hemodiafiltration, or HDF, modality to deliver therapy for ESRD patients. These are the OLpur mid-dilution HDF filter or “dialyzer,” designed expressly for HDF therapy, and the OLpur H2H HDF module, an add-on module designed to allow the most common types of hemodialysis machines to be used for HDF therapy. In 2009, the Company introduced its Dual Stage Ultrafilter (“DSU”) water filter, which represented a new and complementary product line to the Company’s ESRD therapy business. The DSU incorporates the Company’s unique and proprietary dual stage filter architecture.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 4, 2003, Nephros International Limited was incorporated under the laws of Ireland as a wholly-owned subsidiary of the Company.  In August 2003, the Company established a European Customer Service and financial operations center in Dublin, Ireland.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	dei	Document Type DocumentType	10-Q
CY2015Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1230000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-4000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	185000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	32000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2242693	shares
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	1191000	USD
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In Two Years ExpectedRecognitionOfUnrecognizedCompensationCostsDueInTwoYears	0.21	pure
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In Fourth Years ExpectedRecognitionOfUnrecognizedCompensationCostsDueInFourthYears	0.07	pure
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In Fifth Years ExpectedRecognitionOfUnrecognizedCompensationCostsDueInFifthYears	0.04	pure
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	233000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-66000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-43000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	170000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-35000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-867000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1451000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2013000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1205000	USD
	us-gaap	Depreciation Depreciation	5000	USD
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4685000	USD
	us-gaap	Depreciation Depreciation	1000	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	105000	USD
CY2013Q4	us-gaap	Cash Cash	579000	USD
	us-gaap	Interest Paid InterestPaid	54000	USD
	us-gaap	Interest Paid InterestPaid	25000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	167000	USD
	neph	Stock Based Compensation Recognized Amortization Cost StockBasedCompensationRecognizedAmortizationCost	990000	USD
CY2015Q2	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	0.67
CY2015Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.85
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1000	USD
	us-gaap	Effect Of Exchange Rate On Cash Continuing Operations EffectOfExchangeRateOnCashContinuingOperations	-2000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-354000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-247000	USD
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	1500000	USD
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	515000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1206000	USD
	us-gaap	Effect Of Exchange Rate On Cash Continuing Operations EffectOfExchangeRateOnCashContinuingOperations	-2000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	188000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	7436000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.229	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0153	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M24D
CY2015Q2	neph	Royalty Receivable RoyaltyReceivable	28000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	295000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	110000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	419000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	186000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	61000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	104000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	1812000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	1684000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1579000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1684000	USD
CY2015Q2	us-gaap	Assets Assets	3391000	USD
CY2014Q4	us-gaap	Assets Assets	3369000	USD
CY2014Q4	us-gaap	Cash Cash	1284000	USD
CY2015Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1196000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	153000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-46000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-36000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-134000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	24000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3000	USD

Files In Submission

Name	View Source	Status
0001144204-15-047743-index-headers.html	Edgar Link	pending
0001144204-15-047743-index.html	Edgar Link	pending
0001144204-15-047743.txt	Edgar Link	pending
0001144204-15-047743-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
neph-20150630.xml	Edgar Link	completed
neph-20150630.xsd	Edgar Link	pending
neph-20150630_cal.xml	Edgar Link	unprocessable
neph-20150630_def.xml	Edgar Link	unprocessable
neph-20150630_lab.xml	Edgar Link	unprocessable
neph-20150630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v414845_10q.htm	Edgar Link	pending
v414845_ex10-4.htm	Edgar Link	pending
v414845_ex10-5.htm	Edgar Link	pending
v414845_ex31-1.htm	Edgar Link	pending
v414845_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NEPH
NEPHROS INC Stock $neph

2015 Q2 Form 10-Q Financial Statement

#000114420415047743 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEPH NEPHROS INC Stock $neph

2015 Q2 Form 10-Q Financial Statement

#000114420415047743 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEPH
NEPHROS INC Stock $neph